Retrieve available abstracts of 41 articles: HTML format
Single Articles
June 2025
LENTZ RJ, Frederick-Dyer K, Planz VB, Koyama T, et al Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.
N Engl J Med. 2025;392:2100-2112. PubMedAbstract available
MOUNTZIOS G, Sun L, Cho BC, Demirci U, et al Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502099. PubMedAbstract available
FORDE PM, Spicer JD, Provencio M, Mitsudomi T, et al Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502931. PubMedAbstract available
April 2025
HEYMACH JV, Ruiter G, Ahn MJ, Girard N, et al Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
N Engl J Med. 2025 Apr 28. doi: 10.1056/NEJMoa2503704. PubMedAbstract available
PICH O, Bernard E, Zagorulya M, Rowan A, et al Tumor-Infiltrating Clonal Hematopoiesis.
N Engl J Med. 2025;392:1594-1608. PubMedAbstract available
December 2024
SENAN S Durvalumab in Small-Cell Lung Cancer. Reply.
N Engl J Med. 2024;391:2386. PubMed
PETRELLI F, Dottorini L, Ghidini A Durvalumab in Small-Cell Lung Cancer.
N Engl J Med. 2024;391:2385-2386. PubMed
RAMELLA S, Ippolito E, D'Angelillo RM Durvalumab in Small-Cell Lung Cancer.
N Engl J Med. 2024;391:2385. PubMed
October 2024
CHO BC, Lu S, Felip E, Spira AI, et al Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
N Engl J Med. 2024;391:1486-1498. PubMedAbstract available
September 2024
CHENG Y, Spigel DR, Cho BC, Laktionov KK, et al Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
N Engl J Med. 2024 Sep 13. doi: 10.1056/NEJMoa2404873. PubMedAbstract available
WITTROCK E, Hagner MD Cannonball Pulmonary Lesions.
N Engl J Med. 2024;391:844. PubMed
August 2024
LEIGHL NB Osimertinib in Stage III EGFR-Mutated NSCLC - Game, Set, Match.
N Engl J Med. 2024;391:652-654. PubMed
LU S, Kato T, Dong X, Ahn MJ, et al Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
N Engl J Med. 2024;391:585-597. PubMedAbstract available
CASCONE T, Spicer JD, Provencio Pulla M Perioperative Nivolumab in Resectable Lung Cancer. Reply.
N Engl J Med. 2024;391:573-574. PubMed
SORSCHER S Perioperative Nivolumab in Resectable Lung Cancer.
N Engl J Med. 2024;391:573. PubMed
SOBRERO S, Vaisitti F, Leo F Perioperative Nivolumab in Resectable Lung Cancer.
N Engl J Med. 2024;391:572-573. PubMed
June 2024
VIDULA N, Rodriguez K, Wong AK, Boyraz B, et al Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer.
N Engl J Med. 2024;390:2011-2022. PubMed
May 2024
GARASSINO MC, Torri V Neoadjuvant or Perioperative Approach in Lung Cancer.
N Engl J Med. 2024;390:1816-1818. PubMed
CASCONE T, Awad MM, Spicer JD, He J, et al Perioperative Nivolumab in Resectable Lung Cancer.
N Engl J Med. 2024;390:1756-1769. PubMedAbstract available
April 2024
PASSARO A, Peters S Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now.
N Engl J Med. 2024;390:1325-1327. PubMed
WU YL, Dziadziuszko R, Ahn JS, Barlesi F, et al Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2024;390:1265-1276. PubMedAbstract available
IZZEDINE H, Bouderlique E, Besse B Selpercatinib and Pseudo-Decreases in Kidney Function.
N Engl J Med. 2024;390:1241-1243. PubMed
February 2024
ZHOU C, Agrawal T, Girard N VTE with Amivantamab plus Chemotherapy in NSCLC. Reply.
N Engl J Med. 2024;390:579-580. PubMed
MOIK F, Riedl JM, Ay C VTE with Amivantamab plus Chemotherapy in NSCLC.
N Engl J Med. 2024;390:578-579. PubMed
PLANCHARD D, Janne PA, Kobayashi K Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.
N Engl J Med. 2024;390:478-479. PubMed
VAN WAALWIJK VAN DOORN-KHOSROV, Badrising SK, Burgers S Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.
N Engl J Med. 2024;390:478. PubMed
January 2024
HEYMACH JV, Harpole D, Reck M Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply.
N Engl J Med. 2024;390:287-288. PubMed
HORITA N, Fujiwara Y Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
N Engl J Med. 2024;390:287. PubMed
DRILON A, Camidge DR, Lin JJ, Kim SW, et al Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2024;390:118-131. PubMedAbstract available
November 2023
ZHOU C, Tang KJ, Cho BC, Liu B, et al Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
N Engl J Med. 2023;389:2039-2051. PubMedAbstract available
PLANCHARD D, Janne PA, Cheng Y, Yang JC, et al Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
N Engl J Med. 2023;389:1935-1948. PubMedAbstract available
MULLIGAN L Selective RET Kinase Inhibitors and Lung Cancer.
N Engl J Med. 2023;389:1913-1916. PubMed
MCCANNON JB, Shepard JO, Wong AK, Thomas MF, et al Case 35-2023: A 38-Year-Old Woman with Waxing and Waning Pulmonary Nodules.
N Engl J Med. 2023;389:1902-1911. PubMed
ZHOU C, Solomon B, Loong HH, Park K, et al First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive
NSCLC.
N Engl J Med. 2023;389:1839-1850. PubMedAbstract available
WU YL, Zhou Q Combination Therapy for EGFR-Mutated Lung Cancer.
N Engl J Med. 2023 Nov 8. doi: 10.1056/NEJMe2311559. PubMed
October 2023
HEYMACH JV, Harpole D, Mitsudomi T, Taube JM, et al Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
N Engl J Med. 2023 Oct 23. doi: 10.1056/NEJMoa2304875. PubMedAbstract available
AHN MJ, Cho BC, Felip E, Korantzis I, et al Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
N Engl J Med. 2023 Oct 20. doi: 10.1056/NEJMoa2307980. PubMedAbstract available
PROVENCIO M, Massuti B, Romero A Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer. Reply.
N Engl J Med. 2023;389:1534-1535. PubMed
VERMA S, Vincent M, Breadner D Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer.
N Engl J Med. 2023;389:1534. PubMed
TSUBOI M, Herbst RS, Wu YL Osimertinib in Resected EGFR-Mutated NSCLC. Reply.
N Engl J Med. 2023;389:1342. PubMed
DI MAIO M Osimertinib in Resected EGFR-Mutated NSCLC.
N Engl J Med. 2023;389:1341-1342. PubMed